Elevance Health Inc Registered Shs Stock , ELV

388.92 -0.67 -0.17%

10:59:59 AM BTT

News

On Tuesday morning 06/10/2025 the Elevance Health Inc Registered Shs share started trading at the price of $387.92. Compared to the closing price on Monday 06/09/2025 on BTT of $389.59, this is a drop of 0.43%. There are 225.94 M shares outstanding in Elevance Health Inc Registered Shs, which values the company at $72.49 B.

Is Elevance Health stock a Buy, Sell or Hold?

Elevance Health stock has received a consensus rating of buy. The average rating score is and is based on 47 buy ratings, 3 hold ratings, and 0 sell ratings.

What was the 52-week low for Elevance Health stock?

The low in the last 52 weeks of Elevance Health stock was 357.45. According to the current price, Elevance Health is 108.80% away from the 52-week low.

What was the 52-week high for Elevance Health stock?

The high in the last 52 weeks of Elevance Health stock was 567.31. According to the current price, Elevance Health is 68.56% away from the 52-week high.

What are analysts forecasts for Elevance Health stock?

The 50 analysts offering price forecasts for Elevance Health have a median target of 559.69, with a high estimate of 649.00 and a low estimate of 405.40. The median estimate represents a 69.49 difference from the last price of 388.92.

Elevance Health Stock Snapshot

388.67

1.00

388.93

7.00

6/10/2025

10:59 AM

8,755.00

389.59

387.92

88.08 B

225.94 M

385.99

389.69

388.92

357.45

567.31

388.92

6.52

1.77

14.37

99.83

25.68

181.62

24.94

Elevance Health News More News

TipRanks 1d

Elevance Health price target lowered to $500 from $510 at Truist

TipRanks 1d

Elevance Health (ELV) Receives a Buy from Truist Financial

TipRanks 4d

Elevance Health (ELV) Gets a Buy from Bernstein

TipRanks 4d

Trump Trade: Tesla bouncing back after $152B in market cap loss amid Musk spat

TipRanks 4d

Wall Street Analysts Are Bullish on Top Healthcare Picks

Historical Prices for Elevance Health

Loading..
Date	Open	Close	Daily High	Daily Low

Price change over selected period: 0% 0

Elevance Health Analyst Data

Total Analysts: 50

Buy Ratings: 47 Neutral Ratings: 3 Sell Ratings: 0

Price *Price Target

Lowest: 405.40 Median: 559.69 Highest: 649.00

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Elevance Health Analyst Opinions

Date	Analyst	Rating	Price
06/04/25	RBC Capital Markets	Maintained Buy	$478	gut
06/02/25	Barclays Capital	Maintained Buy	$480	gut
04/23/25	RBC Capital Markets	Maintained Buy	$478	gut
04/23/25	Guggenheim	Maintained Buy	$518	gut
04/23/25	Cantor Fitzgerald	Maintained Buy	$485	gut
04/23/25	Barclays Capital	Maintained Buy	$522	gut
04/15/25	Baird Patrick & Co	Downgraded to Hold	$529	neutral
04/09/25	Guggenheim	Maintained Buy	$518	gut
04/09/25	Mizuho	Maintained Buy	$505	gut
01/29/25	Argus Research Company	Maintained Hold	$405.399993896484	neutral
01/28/25	Wells Fargo & Co	Maintained Buy	$478	gut
01/24/25	Cantor Fitzgerald	Maintained Buy	$485	gut
01/24/25	Barclays Capital	Maintained Buy	$512	gut
07/23/24	Cantor Fitzgerald	Maintained Buy	$600	gut
07/22/24	Wells Fargo & Co	Maintained Buy	$593	gut
07/18/24	Barclays Capital	Maintained Buy	$611	gut
07/18/24	RBC Capital Markets	Maintained Buy	$585	gut
07/18/24	Bank of America Merrill Lynch	Downgraded to Hold	$530	neutral
07/10/24	Cantor Fitzgerald	Maintained Buy	$600	gut
06/24/24	Morgan Stanley	Maintained Buy	$643	gut
06/12/24	Cantor Fitzgerald	Maintained Buy	$600	gut
06/11/24	Stephens Inc.	Maintained Buy	$615	gut
06/04/24	Bank of America Merrill Lynch	Maintained Buy	$646	gut
05/30/24	J.P. Morgan	Maintained Buy	$631	gut
05/30/24	Baird Patrick & Co	Maintained Buy	$649	gut
04/24/24	Mizuho	Maintained Buy	$585	gut
04/19/24	RBC Capital Markets	Maintained Buy	$575	gut
04/19/24	UBS	Maintained Buy	$605	gut
04/19/24	Wells Fargo & Co	Maintained Buy	$600	gut
04/19/24	Jefferies & Company Inc.	Maintained Buy	$604	gut
04/19/24	Barclays Capital	Maintained Buy	$621	gut
04/10/24	Cantor Fitzgerald	Maintained Buy	$580	gut
04/08/24	Wells Fargo & Co	Maintained Buy	$557	gut
04/04/24	Cantor Fitzgerald	Maintained Buy	$580	gut
03/06/24	Barclays Capital	Maintained Buy	$584	gut
02/14/24	Cantor Fitzgerald	Maintained Buy	$580	gut
02/02/24	Cantor Fitzgerald	Maintained Buy	$547	gut
01/25/24	Cantor Fitzgerald	Maintained Buy	$547	gut
01/25/24	RBC Capital Markets	Maintained Buy	$574	gut
01/19/24	Cantor Fitzgerald	Maintained Buy	$547	gut
11/21/23	Cantor Fitzgerald	Maintained Buy	$547	gut
11/17/23	J.P. Morgan	Maintained Buy	$552	gut
10/19/23	Cantor Fitzgerald	Maintained Buy	$547	gut
10/19/23	Morgan Stanley	Maintained Buy	$587	gut
09/14/23	Cantor Fitzgerald	Maintained Buy	$547	gut
07/25/23	Morgan Stanley	Maintained Buy	$585	gut
07/20/23	RBC Capital Markets	Maintained Buy	$572	gut
07/20/23	Stephens Inc.	Maintained Buy	$555	gut
07/13/23	UBS	Maintained Buy	$575	gut
07/12/23	Wolfe Research	Downgraded to Hold		neutral

Elevance Health Estimates* in USD

	2025	2026	2027	2028	2029
Revenue	195,225	209,366	224,172	246,117	272,250
Dividend	6.77	7.26	7.42	8.65	-
Dividend Yield (in %)	1.74 %	1.86 %	1.90 %	2.22 %	-
EPS	34.48	39.18	44.70	52.71	60.06
P/E Ratio	11.30	9.94	8.71	7.39	6.49
EBIT	10,579	11,929	13,385	15,406	16,968
EBITDA	11,705	13,032	13,813	14,153	15,433
Net Profit	7,719	8,538	9,589	10,814	12,032
Net Profit Adjusted	7,719	8,538	9,589	10,814	12,032
Pre-Tax Profit	9,453	10,890	12,330	13,939	15,440
Pre-Tax Profit Reported	9,428	10,828	12,334	-	-
EPS (Non-GAAP) ex. SOE	30.48	35.13	39.67	-	-
EPS (GAAP)	31.87	37.68	43.64	50.72	58.02
Gross Income	40,210	43,862	47,266	-	-
Cash Flow from Investing	-3,209	-3,659	-3,604	-5,154	-5,719
Cash Flow from Operations	7,758	9,745	11,013	12,390	13,762
Cash Flow from Financing	-4,273	-4,184	-4,583	-5,451	-5,828
Cash Flow per Share	35.45	41.55	48.27	-	-
Free Cash Flow	6,746	9,518	9,903	11,121	12,417
Free Cash Flow per Share	-	-	-	-	-
Book Value per Share	204.97	240.68	280.15	-	-
Net Debt	20,265	18,283	3,881	21,094	19,114
Research & Development Exp.	-	-	-	-	-
Capital Expenditure	513	1,132	1,229	1,150	1,212
Selling, General & Admin. Exp.	19,688	20,978	23,048	26,168	30,659
Shareholder’s Equity	44,784	49,200	54,050	57,504	63,565
Total Assets	121,746	127,919	134,409	139,199	147,375

	Previous Quarter ending 03/31/25	Current Quarter ending 06/30/25	Next Quarter ending 09/30/25	Current Year ending 12/31/25	Next Year ending 12/31/26
Earnings Estimates
No. of Analysts	-	20	20	21	20
Average Estimate	-	9.200 USD	8.635 USD	34.480 USD	39.178 USD
Year Ago	-	9.905 USD	4.381 USD	25.809 USD	-
Publish Date	-	7/16/2025	10/15/2025	-	-
Revenue Estimates
No. of Analysts	-	-	-	16	14
Average Estimate	-	-	-	195,225 USD	209,366 USD
Year Ago	-	-	-	176,810 USD	-
Publish Date	-	-	-	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

	2024	2023	2022	2021	2020	2019	2018
Sales	176,810.00	171,340.00	156,595.00	138,639.00	121,867.00	104,213.00	92,105.00
Change of sales in %	3.19	9.42	12.95	13.76	16.94	13.15	2.29
Gross profit on sales	-	-	-	-	-	-	-
Gross profit on sales change in %	-	-	-	-	-	-	-
Operating income	8,888.00	8,745.00	8,659.00	8,946.00	7,711.00	6,733.00	5,837.00
Operating income change in %	1.64	0.99	-3.21	16.02	14.53	15.35	17.09
Income before tax	7,904.00	7,715.00	7,769.00	7,925.00	6,238.00	5,985.00	5,068.00
Income before tax change in %	2.45	-0.70	-1.97	27.04	4.23	18.09	27.86
Income after tax	5,980.00	5,987.00	6,025.00	6,104.00	4,572.00	4,807.00	3,750.00
Income after tax change in %	-0.12	-0.63	-1.29	33.51	-4.89	28.19	-2.41

Balance Sheet in Mio. USD

	2024	2023	2022	2021	2020	2019	2018
Total liabilities	75,463.00	69,523.00	66,378.00	61,332.00	55,077.00	46,526.00	43,929.00
Long-term liabilities per share	-	-	-	-	-	-	-
Equity	41,426.00	39,405.00	36,394.00	36,128.00	33,199.00	31,728.00	28,541.00
Equity change in %	5.11	8.26	0.68	8.62	4.64	11.17	7.69
Balance sheet total	116,889.00	108,928.00	102,772.00	97,460.00	88,276.00	78,254.00	72,470.00
Balance sheet total change in %	7.31	5.99	5.45	10.40	12.81	7.98	1.41

Key Data in USD

	2024	2023	2022	2021	2020	2019	2018
Sales per share	759.17	721.74	644.95	561.75	479.23	400.36	348.62
P/E ratio (year end quote, basic EPS)	14.37	18.70	20.67	18.74	17.86	16.35	18.50
P/E ratio (year end quote, diluted EPS)	14.37	18.70	20.67	18.74	17.86	16.35	18.50
Dividend yield in %	1.77	1.26	1.00	0.98	1.18	1.06	1.14
Equity ratio in %	35.44	36.18	35.41	37.07	37.61	40.54	39.38
Debt ratio in %	64.56	63.82	64.59	62.93	62.39	59.46	60.62

Elevance Health Insider Activity

Name	Date	shares traded	shares held	Price	type (sell/buy)	option
CLARK R KERRY	05/13/2025	601.00	9,640.00	n/a	Buy	No
Kaye Mark	04/23/2025	4,588.00	18,977.00	424.82	Sell	No
Penczek Ronald W	03/09/2025	443.00	1,847.00	415.13	Sell	No
Kendrick Charles Morgan JR	03/04/2025	3,504.00	10,116.00	396.30	Sell	No
Kendrick Charles Morgan JR	03/02/2025	2,221.00	7,089.00	395.50	Sell	No
Kaye Mark	03/02/2025	270.00	19,961.00	395.50	Sell	No
BOUDREAUX GAIL	03/02/2025	10,396.00	116,313.00	395.50	Sell	No
LAVU RATNAKAR	03/02/2025	312.00	2,444.00	395.50	Sell	No
Kendrick Charles Morgan JR	03/02/2025	3,686.00	13,620.00	n/a	Buy	No
Kendrick Charles Morgan JR	03/02/2025	2,845.00	9,934.00	n/a	Buy	No
BOUDREAUX GAIL	03/02/2025	15,587.00	142,520.00	n/a	Buy	No
Kaye Mark	03/02/2025	3,604.00	23,565.00	n/a	Buy	No
BOUDREAUX GAIL	03/02/2025	10,620.00	126,933.00	n/a	Buy	No
LAVU RATNAKAR	03/02/2025	2,339.00	4,783.00	n/a	Buy	No
Kendrick Charles Morgan JR	10/31/2024	846.00	7,577.00	414.01	Sell	No
Haytaian Peter D	10/31/2024	1,649.00	17,238.00	414.01	Sell	No
Kendrick Charles Morgan JR	10/31/2024	1,710.00	9,287.00	n/a	Buy	No
Haytaian Peter D	10/31/2024	3,799.00	21,037.00	n/a	Buy	No
Kendrick Charles Morgan JR	10/17/2024	7,417.00	8,423.00	432.14	Sell	No
Kaye Mark	10/01/2024	2,818.00	20,213.00	505.16	Sell	No
PERU RAMIRO G	08/04/2024	753.00	8,744.00	531.52	Sell	No
BOUDREAUX GAIL	07/21/2024	20,779.00	138,830.00	500.36	Sell	No
BOUDREAUX GAIL	07/21/2024	2,250.00	126,709.00	504.27	Sell	No
BOUDREAUX GAIL	07/21/2024	1,100.00	159,609.00	498.50	Sell	No
BOUDREAUX GAIL	07/21/2024	1,000.00	128,959.00	503.67	Sell	No

Elevance Health Dividend Calendar

Date	Name	Dividend	*yield	Currency
2024	Elevance Health Inc Registered Shs	6.52	1.77	USD
2023	Elevance Health Inc Registered Shs	5.92	1.26	USD
2022	Elevance Health Inc Registered Shs	5.12	1.00	USD
2021	Elevance Health Inc Registered Shs	4.52	0.98	USD
2020	Elevance Health Inc Registered Shs	3.80	1.18	USD
2019	Elevance Health Inc Registered Shs	3.20	1.06	USD
2018	Elevance Health Inc Registered Shs	3.00	1.14	USD
2017	Elevance Health Inc Registered Shs	2.70	1.20	USD
2016	Elevance Health Inc Registered Shs	2.60	1.81	USD
2015	Elevance Health Inc Registered Shs	2.50	1.79	USD
2014	Elevance Health Inc Registered Shs	1.75	1.39	USD
2013	Elevance Health Inc Registered Shs	1.50	1.62	USD
2012	Elevance Health Inc Registered Shs	1.15	1.89	USD
2011	Elevance Health Inc Registered Shs	1.00	1.51	USD
2010	Elevance Health Inc Registered Shs	0.00	0.00	USD
2009	Elevance Health Inc Registered Shs	0.00	0.00	USD
2008	Elevance Health Inc Registered Shs	0.00	0.00	USD
2007	Elevance Health Inc Registered Shs	0.00	0.00	USD
2006	Elevance Health Inc Registered Shs	0.00	0.00	USD
2005	Elevance Health Inc Registered Shs	0.00	0.00	USD
2004	Elevance Health Inc Registered Shs	0.00	0.00	USD
2003	Elevance Health Inc Registered Shs	0.00	0.00	USD
2002	Elevance Health Inc Registered Shs	0.00	0.00	USD
2001	Elevance Health Inc Registered Shs	0.00	0.00	USD
2000	Elevance Health Inc Registered Shs	0.00	0.00	USD
1999	Elevance Health Inc Registered Shs	0.00	0.00	USD

*Yield of the Respective Date

Elevance Health Calendar

Event	Estimate	Info	Date
Earnings Report	9.200 USD	Q2 2025 Earnings Release	07/16/2025
Earnings Report	8.635 USD	Q3 2025 Earnings Release	10/15/2025
Earnings Report	4.566 USD	Q4 2025 Earnings Release	01/28/2026
Earnings Report	13.171 USD	Q1 2026 Earnings Release	04/22/2026

Elevance Health Past Events

Event	Actual EPS	Info	Date
Annual General Meeting	25.680 USD	Annual General Meeting	05/14/2025
Earnings Report	9.610 USD	Q1 2025 Earnings Release	04/22/2025
Earnings Report	1.810 USD	Q4 2024 Earnings Release	01/23/2025
Earnings Report	4.360 USD	Q3 2024 Earnings Release	10/17/2024
Earnings Report	9.850 USD	Q2 2024 Earnings Release	07/17/2024
Annual General Meeting	25.220 USD	Annual General Meeting	05/15/2024
Earnings Report	9.590 USD	Q1 2024 Earnings Release	04/18/2024
Earnings Report	3.630 USD	Q4 2023 Earnings Release	01/24/2024
Earnings Report	5.450 USD	Q3 2023 Earnings Release	10/18/2023
Earnings Report	7.790 USD	Q2 2023 Earnings Release	07/19/2023
Annual General Meeting	24.810 USD	Annual General Meeting	05/10/2023
Earnings Report	8.300 USD	Q1 2023 Earnings Release	04/19/2023
Earnings Report	3.930 USD	Q4 2022 Earnings Release	01/25/2023
Earnings Report	6.680 USD	Q3 2022 Earnings Release	10/19/2022
Earnings Report	6.790 USD	Q2 2022 Earnings Release	07/20/2022
Annual General Meeting	24.730 USD	Annual General Meeting	05/18/2022
Earnings Report	7.390 USD	Q1 2022 Earnings Release	04/20/2022
Earnings Report	4.630 USD	Q4 2021 Earnings Release	01/26/2022

Elevance Health Profile

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Elevance Health Management

Name	Job
Ronald William Penczek	Chief Accounting Officer & Controller
Marcus D. Wilson	Chief Analytics Officer
Ratnakar Lavu	Chief Digital & Information Officer & Executive VP
Mark B. Kaye	Chief Financial Officer & Executive Vice President
Shantanu Agrawal	Chief Health Officer
Dustin Wilcox	Chief Information Security Officer
Kyle Weber	Chief Strategy Officer
Hakon Mattson	Chief Sustainability Officer
Peter David Haytaian	Executive VP, President-Carelon & CarelonRX
Antonio Fabio Neri	Independent Director
Bahija Jallal	Independent Director
Deanna Dawnette Strable-Soethout	Independent Director
Lewis Hay	Independent Director
R. Kerry Clark	Independent Director
Ramiro G. Peru	Independent Director
Robert L. Dixon	Independent Director
Ryan M. Schneider	Independent Director
Susan D. DeVore	Independent Director
Gail Koziara Boudreaux	President, Chief Executive Officer & Director
Morgan Kendrick	President-Commercial Health Benefits & EVP
Scott Towers	President-Dental Business
Felicia Farr Norwood	President-Government Health Benefits & EVP
Bryony Winn	President-Health Solutions
Kathleen S. Kiefer	Secretary & Chief Governance Officer
Chris Rigg	Senior VP & CFO-Commercial & Specialty Business
Rachel Stuve	Sr. Director Data Science & AI
Nathan Rich	Vice President-Investor Relations
Jill A. Becher	Vice President-Planning & Execution